Sirolimus-eluting coronary stent - JW Medical Systems

Drug Profile

Sirolimus-eluting coronary stent - JW Medical Systems

Alternative Names: Excel; Excel DES; Excel-II

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JW Medical Systems
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease
  • Phase II/III Coronary artery restenosis

Most Recent Events

  • 17 Mar 2016 EXCEL-II sirolimus-eluting coronary stent is still in phase II/III trials for Coronary artery disease (Treatment-naive) and Coronary artery restenosis (Prevention) in China
  • 15 Mar 2016 Biomarkers information updated
  • 12 Feb 2015 JW Medical systems completes enrolment in its phase II trial for Coronary artery disease (treatment naive) in China (9174729; NCT02057978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top